TY - JOUR
T1 - Efficacy of Cognitive-Behavioral Therapy Targeting Severe Fatigue Following Coronavirus Disease 2019
T2 - Results of a Randomized Controlled Trial
AU - Kuut, Tanja A.
AU - Müller, Fabiola
AU - Csorba, Irene
AU - Braamse, Annemarie
AU - Aldenkamp, Arnoud
AU - Appelman, Brent
AU - Assmann-Schuilwerve, Eleonoor
AU - Geerlings, Suzanne E.
AU - Gibney, Katherine B.
AU - Kanaan, Richard A. A.
AU - Mooij-Kalverda, Kirsten
AU - Hartman, Tim C. Olde
AU - Pauëlsen, Dominique
AU - Prins, Maria
AU - Slieker, Kitty
AU - van Vugt, Michele
AU - Keijmel, Stephan P.
AU - Nieuwkerk, Pythia
AU - Rovers, Chantal P.
AU - Knoop, Hans
N1 - Funding Information: Potential conflicts of interest. F. M. reports funding from the Nederlands Kenniscentrum Chronische Vermoeidheid (NKCV) Foundation. C. P. R. reports grants as a payment to institution by the present study, the European Union Horizon 2020 Research and Innovation Framework Programme, and the Michael J. Fox Foundation; and has served as a member of the committee “Pandemic Preparedness Plan” of the Royal Netherlands Academy of Arts and Sciences and a member of the committee “Long-term effects of COVID-19” of the Health Council of the Netherlands. K. B. G. reports salary support (investigator grant [MRF1193727] 2021–2025) by the MRFF/NHMRC, Australia; grants from the Partnership Project (APP1196396 2020–2023, APP152807) and an Early Career Fellowship (APP1120816) by the NHMRC; Faculty of Medicine, Dentistry and Health Sciences (MDHS) Research Grant Support Scheme 2020 by the University of Melbourne; a Research Establishment Fellowship 2020 by the Royal Australasian College of Physicians–GlaxoSmithKline; Seed Funding 2019 by the Melbourne Children's Research Institute; royalties for textbook (Manual of Travel Medicine Edition 4) by Springer Nature Singapore; and being a member of the Australian Technical Advisory Group of Immunisation and an expert member (representing the Australasian Society of Infectious Diseases) of the Communicable Diseases Network Australia. R. A. A. K. reports grants or contracts from MRFF/NHMRC, Mindgardens Neuroscience Network, and Austin Medical Research Foundation; and has served as advisory board member of the Psychae Institute, director of the Functional Neurological Disorder Society, director of the International Neuropsychiatry Association, and member of the Biotoxin-Related Illness Advisory Committee, Australian Department of Health. H. K. was supported for this study by the Netherlands Organization for Health Research and Development (ZonMw: project number 10430012010025, research program COVID-19), with payments made to institution; and grants from ZonMw to conduct research into long COVID and post-Lyme symptoms, from the Dutch Cancer Society, Multiple Sclerose research, Pfizer, and NKCV Foundation. All other authors report no potential conflicts. Funding Information: Financial support. This work was supported by the Netherlands Organization for Health Research and Development (ZonMw: project number 10430012010025, research program COVID-19). K. B. G. was also supported in part by the Medical Research Future Fund (MRFF), National Health and Medical Research Council (NHMRC), Australia (Investigator Grant MRF1193727). Publisher Copyright: © 2023 The Author(s).
PY - 2023/9/1
Y1 - 2023/9/1
N2 - Background: Severe fatigue following coronavirus disease 2019 (COVID-19) is prevalent and debilitating. This study investigated the efficacy of cognitive-behavioral therapy (CBT) for severe fatigue following COVID-19. Methods: A multicenter, 2-arm randomized controlled trial was conducted in the Netherlands with patients being severely fatigued 3-12 months following COVID-19. Patients (N = 114) were randomly assigned (1:1) to CBT or care as usual (CAU). CBT, targeting perpetuating factors of fatigue, was provided for 17 weeks. The primary outcome was the overall mean difference between CBT and CAU on the fatigue severity subscale of the Checklist Individual Strength, directly post-CBT or CAU (T1), and after 6 months (T2). Secondary outcomes were differences in proportions of patients meeting criteria for severe and/or chronic fatigue, differences in physical and social functioning, somatic symptoms, and problems concentrating between CBT and CAU. Results: Patients were mainly nonhospitalized and self-referred. Patients who received CBT were significantly less severely fatigued across follow-up assessments than patients receiving CAU (-8.8 [95% confidence interval {CI}, -11.9 to -5.8]); P <. 001), representing a medium Cohen's d effect size (0.69). The between-group difference in fatigue severity was present at T1 (-9.3 [95% CI, -13.3 to -5.3]) and T2 (-8.4 [95% CI, -13.1 to -3.7]). All secondary outcomes favored CBT. Eight adverse events were recorded during CBT, and 20 during CAU. No serious adverse events were recorded. Conclusions: Among patients, who were mainly nonhospitalized and self-referred, CBT was effective in reducing fatigue. The positive effect was sustained at 6-month follow-up. Clinical Trials Registration: Netherlands Trial Register NL8947.
AB - Background: Severe fatigue following coronavirus disease 2019 (COVID-19) is prevalent and debilitating. This study investigated the efficacy of cognitive-behavioral therapy (CBT) for severe fatigue following COVID-19. Methods: A multicenter, 2-arm randomized controlled trial was conducted in the Netherlands with patients being severely fatigued 3-12 months following COVID-19. Patients (N = 114) were randomly assigned (1:1) to CBT or care as usual (CAU). CBT, targeting perpetuating factors of fatigue, was provided for 17 weeks. The primary outcome was the overall mean difference between CBT and CAU on the fatigue severity subscale of the Checklist Individual Strength, directly post-CBT or CAU (T1), and after 6 months (T2). Secondary outcomes were differences in proportions of patients meeting criteria for severe and/or chronic fatigue, differences in physical and social functioning, somatic symptoms, and problems concentrating between CBT and CAU. Results: Patients were mainly nonhospitalized and self-referred. Patients who received CBT were significantly less severely fatigued across follow-up assessments than patients receiving CAU (-8.8 [95% confidence interval {CI}, -11.9 to -5.8]); P <. 001), representing a medium Cohen's d effect size (0.69). The between-group difference in fatigue severity was present at T1 (-9.3 [95% CI, -13.3 to -5.3]) and T2 (-8.4 [95% CI, -13.1 to -3.7]). All secondary outcomes favored CBT. Eight adverse events were recorded during CBT, and 20 during CAU. No serious adverse events were recorded. Conclusions: Among patients, who were mainly nonhospitalized and self-referred, CBT was effective in reducing fatigue. The positive effect was sustained at 6-month follow-up. Clinical Trials Registration: Netherlands Trial Register NL8947.
KW - COVID-19
KW - cognitive-behavioral therapy
KW - fatigue
KW - long COVID
UR - http://www.scopus.com/inward/record.url?scp=85172913042&partnerID=8YFLogxK
U2 - https://doi.org/10.1093/cid/ciad257
DO - https://doi.org/10.1093/cid/ciad257
M3 - Article
C2 - 37155736
SN - 1058-4838
VL - 77
SP - 687
EP - 695
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
IS - 5
ER -